William Blair & Company
RNTX

William Blair & Company’s Rein Therapeutics RNTX Stock Holding History

William Blair & Company’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,393
Closed -$26.8K – 1962
2025
Q3 		$26.8K Sell
23,393
-229
-1% -$291 ﹤0.01% 1696
2025
Q2 		$33.1K Hold
23,622
– – ﹤0.01% 1645
2025
Q1 		$41.8K Sell
23,622
-1,980
-8% -$4.16K ﹤0.01% 1609
2024
Q4 		$58.9K Hold
25,602
– – ﹤0.01% 1588
2024
Q3 		$90.6K Sell
25,602
-2,445
-9% -$6.54K ﹤0.01% 1552
2024
Q2 		$77.7K Sell
28,047
-250
-0.9% -$1.03K ﹤0.01% 1544
2024
Q1 		$188K Hold
28,297
– – ﹤0.01% 1416
2023
Q4 		$86.3K Sell
28,297
-700
-2% -$1.36K ﹤0.01% 1524
2023
Q3 		$44.1K Sell
28,997
-670
-2% -$1.14K ﹤0.01% 1599
2023
Q2 		$53.1K Sell
29,667
-2,550
-8% -$3.93K ﹤0.01% 1590
2023
Q1 		$39.9K Sell
32,217
-35,650
-53% -$76.4K ﹤0.01% 1603
2022
Q4 		$161K Buy
67,867
+6,527
+11% +$21.9K ﹤0.01% 1416
2022
Q3 		$254K Buy
61,340
+3,911
+7% +$16.5K ﹤0.01% 1299
2022
Q2 		$299K Buy
57,429
+7,096
+14% +$65.2K ﹤0.01% 1275
2022
Q1 		$516K Sell
50,333
-3,041
-6% -$27.5K ﹤0.01% 1149
2021
Q4 		$601K Buy
53,374
+13,216
+33% +$204K ﹤0.01% 1145
2021
Q3 		$819K Buy
40,158
+5,756
+17% +$126K ﹤0.01% 999
2021
Q2 		$860K Buy
34,402
+17,122
+99% +$427K ﹤0.01% 965
2021
Q1 		$494K Buy
17,280
+3,880
+29% +$133K ﹤0.01% 1127
2020
Q4 		$279K Buy
13,400
+1,308
+11% +$32.7K ﹤0.01% 1304
2020
Q3 		$312K Buy
12,092
+165
+1% +$3.88K ﹤0.01% 1130
2020
Q2 		$281K Sell
11,927
-3,270
-22% -$53.3K ﹤0.01% 1123
2020
Q1 		$101K Sell
15,197
-2,205
-13% -$26.6K ﹤0.01% 1306
2019
Q4 		$199K Buy
17,402
+15,027
+633% +$148K ﹤0.01% 1311
2019
Q3 		$32K Buy
2,375
+210
+10% +$2.9K ﹤0.01% 1496
2019
Q2 		$31K Buy
2,165
+1,072
+98% +$28.1K ﹤0.01% 1543
2019
Q1 		$43K Buy
+1,093
New +$34.1K ﹤0.01% 1490

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

William Blair & Company's RNTX Position: Q4 2025 in Review

William Blair & Company sold out of Rein Therapeutics (RNTX) in Q4 2025, closing a stake of 23,393 shares — an estimated $26.8K sold.

William Blair & Company first reported a position in RNTX in Q1 2019 and held it in 27 quarters. The position peaked at $860K in Q2 2021. 48 funds tracked by Wall St. Rank hold RNTX as of Q4 2025.

  • William Blair & Company reported no remaining Rein Therapeutics position as of Q4 2025 after selling out during the quarter.
  • William Blair & Company sold 23,393 Rein Therapeutics shares in Q4 2025, an estimated $26.8K.
  • William Blair & Company first reported a position in Rein Therapeutics in Q1 2019 and held it in 27 quarters.
  • William Blair & Company's Rein Therapeutics position peaked at $860K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2025.

Based on William Blair & Company's 13F filing for Q4 2025, filed 17 Feb 2026.